 |
Dear Friends,
It is with great pleasure that we present to you the fourth 2010 quarterly issue of the Jerusalem Life Science Bulletin, highlighting the latest achievements and news of Jerusalem's life science cluster.
|
I want to call your attention to two new interesting initiatives of Jerusalem-based academic institutions. The first is by the Pharmaceutical Engineering Department of the Jerusalem College of Engineering (JCE). In the past quarter, JCE launched, with the support of Teva Pharmaceuticals and the Foundation for Development and Progress, four new cutting-edge laboratories spanning 500 square meters built at a total cost of $3 million. The laboratories, equipped with the latest technology, specialize at pharmaceutical technology, chemical technology, analytical chemistry and biology. The college is now seeking collaborations with biotech companies that can benefit from these advanced laboratories and the expertise of the Department's leading scientists. In particular, the pharmaceutical and chemical industries can profit from transforming their production processes to "green", environmentally-friendly processes, and from scaling-up of green chemical processes while receiving analytical support from the laboratory staff. The Departments' staff members have a rich and diverse experience in the development, scaling-up and analysis of industrial chemical processes.
The second initiative is by Hadassah College, which has added a track in M.Sc. studies in Computer Science. This new track has a practical focus, and includes a specialization in "Computers in Medicine". Within the framework of studies, students will acquire targeted technological knowledge and special hardware and software tools that are most relevant to hospitals and the medical device industry. One of the goals of the program is to enhance professional ties with the local industry, thus projects in subjects such as programming, hardware, communications and medicine will be carried out at the College's state-of-art laboratories and in other laboratories in the Capital, such as at Hadassah University Hospital, and in cooperation with the biomed and hi-tech industries.
I would like to end with thanking the Jerusalem biotech companies that participated in the various activities we organized in the recent BioEurope meeting, which took place in November in Munich, Germany. Our session and booth, both of which highlighted the accomplishments of the Jerusalem bio-cluster, were a big success. We look forward to collaborating with you in future international life science conferences.
BioJerusalem's booth at BioEurope
With best wishes,
Chen Levin, Executive Director of BioJerusalem,
The Jerusalem Development Authority
Attracting the life sciences to Jerusalem
If the director of BioJerusalem has her way, Israel's political and spiritual capital may yet become a major center of biotech as well
Biotech - Tailor-made for Israel
Israel creates more medical devices per capita than any other, and earns $3 billion a year from biotech
Diabetes co Oramed gets NIS 2.9m OCS grant
The funds will support further R&D and clinical study of its oral insulin capsule
Sanofi Aventis to invest $5m in Hadasit Bio portfolio co
KAHR Medical is developing protein-based drugs for autoimmune diseases and cancer
UK's Morria plans offering on TASE
Morria's drug pipeline is based on innovative anti-inflammatory technology developed at Hebrew University
14 biomed cos, 6 hours, 60 investors
The TASE-Nasdaq Biomed Conference was organized with the goal of attracting foreign investment to Israeli biomed companies
BiolineRX revenue rises on Cypress deal
CEO Dr. Kinneret Savitsky: These results strengthen our substantial progress, as seen in our net profit, which is not routine for a biotech company
Biocancell secondary offering oversubscribed 74%
Investors apparently sold shares on the market while purchasing shares in the offering
Biocancell sets price range for Nasdaq offering
The cancer treatment developer seeks to raise a gross NIS 15.8-19 million
Intec Pharma raises NIS 14.9m in private placement
The company allotted shares and warrants to Meitav Investment House and Israel Phoenix Assurance
Drug developer Atox Bio raises $2.1m
The company is developing non antibiotic drugs to battle severe infections
Cell Cure Neurosciences’ Shareholders Will Invest $7.1 M in the Company’s Development of Innovative Stem Cell Treatments for Neural and Retinal Diseases
| Clinical & Regulatory News |
BiolineRX reports success in warts removal study
A new drug allows the non-surgical removal of certain noncancerous warts
BioCancell brain cancer preclinical trial successful
BioCancell brain cancer preclinical trial successful
BiolineRX and Cypress on track with schizophrenia drug
The companies are waiting for national regulators to conduct clinical trials
Avraham Pharmaceuticals begins Phase IIb Alzheimer's study
Teva forewent one of the components of the company's drug
Biocancell reports pancreatic trial success
CEO Uri Danon: There was reduction or stability in tumor size in most of the patient
Brainsway reports positive Parkinson's study results
The company now plans a wider clinical trial of its deep TMS therapy
Biocancell tests show drug's effectiveness with Gemzar
Animal tests compared using BC-819 together with Gemzar (Gemcitabine), an FDA-approved drug to treat pancreatic cancer
Biocancell completes pancreatic cancer trial
In August, the FDA granted orphan drug status to BC-819 to treat pancreatic cancer
| Collaborations & Alliances |
Cell Cure Neuroscience Ltd, a Subsidiary of BioTime, Inc. and Hadasit Bio Holdings Ltd., Enters Into An Exclusive License Option Agreement
The Agreement With Teva Pharmaceutical Industries Ltd. is to Develop and Market OpRegenTM for the Treatment of Age-Related Macular Degeneration
| Scientific/Medical Discoveries & Breakthroughs |
Yissum Introduces a Novel Method for Forensic DNA Profiling
Method enables accurate identification of a suspect's DNA in crime scenes even when DNA evidence comprises a mixture from multiple individuals
Researchers warn of stem cell cancer link
Researchers in Israel are warning that stem cell treatments could raise cancer risks
On the HIV warpath
A substance that destroys cells infected with deadly HIV and could prevent AIDS, has been developed in Israel after a decade of cooperation between chemists and biologists
Hebrew University research holds promise for development of new osteoporosis drug
The discovery will enable the development of novel drugs for prevention and treatment of osteoporosis and other bone disorders
|
This newsletter is brought to you by BioJerusalem, an initiative of the Jerusalem Development Authority, committed to building a strong life science industry in Jerusalem.
Please visit www.biojerusalem.org.il or contact us for more information on how BioJerusalem can assist your business.
Liposomes in Jerusalem 2011
May. 15-19, 2011
International Hepatobiliary, Pancreatic, and Transplantation Days
May. 24-28, 2011
Dream Doctors Convention, 2011
Oct. 23-26, 2011
Learn how your organization can benefit form our new bio-internship program.
More
| Financial Incentives for Biomed Companies |
|
Companies located in Jerusalem can benefit from significant governmental and municipal financial support.
More
| Visit BioJerusalem's Database |
|
BioJerusalem’s free online database is the most
comprehensive source of information on life sciences in Jerusalem, including
life science companies, academic research and medical institutions, scientists
and their research, technology transfer companies, research facilities and
equipment, technology parks and incubators, government and local authorities and
service providers.
Search database
For Previous issues of the Life Science Bulletin
Click here.
BioJerusalem
High Tech Village, Bldg. 1-1
Edmond Safra Campus
Givat Ram, P.O.Box 39026
Jerusalem 91390, Israel
Phone: 972-2-5617532
Mobile: 972-50-5511822
Email: info@biojerusalem.org.il
|
